{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:33:26Z","timestamp":1744173206283,"version":"3.40.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1007\/s11908-006-0031-7","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T12:42:46Z","timestamp":1181047366000},"page":"23-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Community-associated methicillin-resistant Staphylococcus aureus: Reconsideration of therapeutic options"],"prefix":"10.1007","volume":"8","author":[{"given":"Matthew E.","family":"Levison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"31_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0378-1119(01)00390-0","volume":"268","author":"S Narita","year":"2001","unstructured":"Narita S, Kaneko J, Chiba J, et al.: Phage conversion of Panton-Valentine leucocidin in Staphylococcus aureus: molecular analysis of a PVL-converting phage, phiSLT. Gene 2001, 268:195\u2013206.","journal-title":"Gene"},{"key":"31_CR2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3201\/eid0908.030089","volume":"9","author":"F Vandenesch","year":"2003","unstructured":"Vandenesch F, Naimi T, Enright MC, et al.: Communityacquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leucocidin genes: worldwide emergence. Emerg Infect Dis 2003, 9:978\u2013984. This study examined 117 CA-MRSA isolates from the United States, France, Switzerland, Australia, New Zealand, and Western Samoa by performing polymerase chain reaction for 24 virulence factors and the SCC type. Within each continent, the genetic background of CA-MRSA strains did not correspond to that of the hospitalacquired MRSA.","journal-title":"Emerg Infect Dis"},{"key":"31_CR3","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/S0140-6736(05)74814-5","volume":"365","author":"DA Robinson","year":"2005","unstructured":"Robinson DA, Kearns AM, Holmes A, et al.: Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet 2005, 365:1256\u20131258.","journal-title":"Lancet"},{"key":"31_CR4","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1128\/AAC.44.6.1549-1555.2000","volume":"44","author":"Y Katayama","year":"2000","unstructured":"Katayama Y, Ito T, Hiramatsu K: A new class of genetic element, Staphylococcal cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000, 44:1549\u20131555.","journal-title":"Antimicrob Agents Chemother"},{"key":"31_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1469-0691.2004.00768.x","volume":"10","author":"DA Robinson","year":"2004","unstructured":"Robinson DA, Enright MC: Multilocus sequence typing and the evolution of methicillin-resistant Staphylococcus aureus. Clin Micobiol Infect 2004, 10:92\u201397.","journal-title":"Clin Micobiol Infect"},{"key":"31_CR6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1086\/344326","volume":"186","author":"RS Daum","year":"2002","unstructured":"Daum RS, Ito T, Hiramatsu K, et al.: A novel methicillin resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002, 186:1344\u20131347.","journal-title":"J Infect Dis"},{"key":"31_CR7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(02)08713-5","volume":"359","author":"T Baba","year":"2002","unstructured":"Baba T, Takeuchi F, Kuroda M, et al.: Genome and virulence determinants of high virulence communityacquired MRSA. Lancet 2002, 359:1819\u20131827.","journal-title":"Lancet"},{"key":"31_CR8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/S0140-6736(01)24468-7","volume":"222","author":"PN Panton","year":"1932","unstructured":"Panton PN, Valentine FCO: Staphylococcal toxin. Lancet 1932, 222:506\u2013508.","journal-title":"Lancet"},{"key":"31_CR9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/iai.28.2.393-397.1980","volume":"28","author":"PD Ward","year":"1980","unstructured":"Ward PD, Turner WH: Identification of staphylococcal Panton-Valentine leucocidin as a potent dermonecrotic toxin. Infect Immun 1980, 28:393\u2013397.","journal-title":"Infect Immun"},{"key":"31_CR10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0140-6736(02)07877-7","volume":"359","author":"Y Gillet","year":"2002","unstructured":"Gillet Y, Issartel B, Vanhems P, et al.: Association between Staphylococcus aureus strains carrying Panton-Valentine leucocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 2002, 359:753\u2013759.","journal-title":"Lancet"},{"key":"31_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1086\/380909","volume":"189","author":"V Gauduchon","year":"2004","unstructured":"Gauduchon V, Cozon G, Vandenesch F, et al.: Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004, 189:346\u2013353.","journal-title":"J Infect Dis"},{"key":"31_CR12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000247443","volume":"185","author":"B Cribier","year":"1992","unstructured":"Cribier B, Prevost G, Couppie P, et al.: Staphylococcus aureus leucocidin: a new virulence factor in cutaneous infections? An epidemiological and experimental study. Dermatology 1992, 185:175\u2013180.","journal-title":"Dermatology"},{"key":"31_CR13","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1086\/313461","volume":"29","author":"G Lina","year":"1999","unstructured":"Lina G, Piemont Y, Godail-Gamot F, et al.: Involvement of Panton-Valentine leucocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999, 29:1128\u20131132.","journal-title":"Clin Infect Dis"},{"key":"31_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-96-1-11","volume":"96","author":"LD Saravolatz","year":"1982","unstructured":"Saravolatz LD, Markowitz N, Arking L, et al.: Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-wide outbreak. Ann Intern Med 1982, 96:11\u201316.","journal-title":"Ann Intern Med"},{"key":"31_CR15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMoa042859","volume":"352","author":"SV Kazakova","year":"2005","unstructured":"Kazakova SV, Hageman JC, Matava M, et al.: A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005, 352:468\u2013475.","journal-title":"N Engl J Med"},{"key":"31_CR16","first-page":"992","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","unstructured":"Centers for Disease Control and Prevention: Methicillinresistant Staphylococcus aureus infections in correctional facilities\u2014Georgia, California, and Texas, 2001\u20132003. MMWR Morb Mortal Wkly Rep 2003, 52:992\u2013996.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"31_CR17","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1001\/jama.286.10.1201","volume":"286","author":"AV Groom","year":"2001","unstructured":"Groom AV, Wolsey DH, Naimi TS, et al.: Communityacquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001, 286:1201\u20131205.","journal-title":"JAMA"},{"key":"31_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1086\/338069","volume":"34","author":"ED Charlebois","year":"2002","unstructured":"Charlebois ED, Bangsberg DR, Moss NJ, et al.: Populationbased community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis 2002, 34:425\u2013433.","journal-title":"Clin Infect Dis"},{"key":"31_CR19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/archinte.158.8.895","volume":"158","author":"JM Lindenmeyer","year":"1998","unstructured":"Lindenmeyer JM, Schoenfeld S, O\u2019Grady R, Carney JK:Methicillin-resistant Staphylococcus aureus in a high school wrestling team and the surrounding community. Arch Intern Med 1998, 158:895\u2013899.","journal-title":"Arch Intern Med"},{"key":"31_CR20","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1086\/429827","volume":"40","author":"NE Lee","year":"2005","unstructured":"Lee NE, Taylor MM, Bancroft E, et al.: Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 2005, 40:1529\u20131534.","journal-title":"Clin Infect Dis"},{"key":"31_CR21","first-page":"707","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","unstructured":"Centers for Disease Control and Prevention: Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997\u20131999. MMWR 1999, 48:707\u2013710.","journal-title":"MMWR"},{"key":"31_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/jama.279.8.593","volume":"279","author":"BC Herold","year":"1998","unstructured":"Herold BC, Immergluck LC, Maranan MC, et al.: Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998, 279:593\u2013598.","journal-title":"JAMA"},{"key":"31_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.annemergmed.2004.10.011","volume":"45","author":"BW Frazee","year":"2005","unstructured":"Frazee BW, Lynn J, Charlebois ED, et al.: High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005, 45:311\u201320. Of 137 adults seen in a California emergency department with skin and soft tissue infection, 70% of nares cultures that tested positive for S. aureus grew MRSA. Of the 119 infection site cultures, two thirds grew S. aureus, of which three quarters were MRSA. Of patients with MRSA infection, about one third had MRSA nasal colonization.","journal-title":"Ann Emerg Med"},{"key":"31_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3201\/eid0702.010204","volume":"7","author":"HF Chambers","year":"2001","unstructured":"Chambers HF: The changing epidemiology of Staphylococcus aureus. Emerg Infect Dis 2001, 7:178\u2013181.","journal-title":"Emerg Infect Dis"},{"key":"31_CR25","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1128\/JCM.37.9.2858-2862.1999","volume":"37","author":"FG O\u2019Brien","year":"1999","unstructured":"O\u2019Brien FG, Pearman JW, Gracey M, et al.: Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol 1999, 37:2858\u20132862.","journal-title":"J Clin Microbiol"},{"key":"31_CR26","volume-title":"Dramatic increase of staphylococcal chromosomal cassette mec (SCC mec) type IV in both a nosocomial and community setting","author":"J Carleton","year":"2003","unstructured":"Carleton J, Charlebois ED, Pedreau-Remington F: Dramatic increase of staphylococcal chromosomal cassette mec (SCC mec) type IV in both a nosocomial and community setting. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago) hington, DC: American Society for Microbiology; 2003."},{"key":"31_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1086\/345436","volume":"36","author":"CD Salgado","year":"2003","unstructured":"Salgado CD, Farr BM, Calfee DF: Community-acquired methicillin-resistant Staphylococcus aureus: a metaanalysis of prevalence and risk factors. Clin Infect Dis 2003, 36:131\u2013136.","journal-title":"Clin Infect Dis"},{"key":"31_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1086\/502227","volume":"24","author":"LB Johnson","year":"2003","unstructured":"Johnson LB, Bhan A, Pawlak J, et al.: Changing epidemiology of community-acquired methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2003, 24:431\u2013435.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"31_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1086\/502223","volume":"24","author":"J Jernigan","year":"2003","unstructured":"Jernigan J, Pullen AL, Partin C, Jarvis WR: Prevalence of and risk factors for colonization with methicillinresistant Staphylococcus aureus in an outpatient clinic population. Infect Control Hosp Epidemiol 2003, 24:445\u2013450.","journal-title":"Infect Control Hosp Epidemiol"},{"unstructured":"Fung S, Levison ME: Low incidence of communityacquired MRSA infections in a Philadelphia acute care teaching hospital. Paper presented at the Infectious Diseases Society of America 42nd Annual Meeting. Boston, MA; September 30\u2013October 3, 2004.","key":"31_CR30"},{"key":"31_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1086\/421090","volume":"39","author":"ED Charlebois","year":"2004","unstructured":"Charlebois ED, Perdreau-Remington F, Kreisworth B, et al.:Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004, 39:47\u201354.","journal-title":"Clin Infect Dis"},{"key":"31_CR32","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa043252","volume":"352","author":"SK Fridkin","year":"2005","unstructured":"Fridkin SK, Hageman JC, Morrison M, et al.: Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352:1436\u20131444. Of 12,500 patients with MRSA isolates identified in a population-based survey in Atlanta and Baltimore, and in 12 hospitals in Minnesota from 2001\u20132002, the annual incidence of CA-MRSA disease was 18 to 25.7 cases\/100,000 population. Although lacking in classical risk factors for MRSA infection, 45% had significant underlying medical conditions that suggested some prior contact with the health care system.","journal-title":"N Engl J Med"},{"key":"31_CR33","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1086\/322693","volume":"33","author":"TS Naimi","year":"2001","unstructured":"Naimi TS, LeDell KH, Boxrud DM, et al.: Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996\u20131998. Clin Infect Dis 2001, 33:990\u2013996.","journal-title":"Clin Infect Dis"},{"key":"31_CR34","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","volume":"115","author":"D Levine","year":"1991","unstructured":"Levine D, Fromm BS, Reddy BR: Slow response to vancomycin or vancomycin plus rifampin in methicillinresistant Staphylococcus aureus endocarditis. Ann Intern Med 1991, 115:674\u2013680.","journal-title":"Ann Intern Med"},{"key":"31_CR35","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1086\/383472","volume":"38","author":"CF Carpenter","year":"2004","unstructured":"Carpenter CF, Chambers HF: Daptomycin: another novel agent for treating infections due to drug-resistant grampositive pathogens. Clin Infect Dis 2004, 38:994\u20131000.","journal-title":"Clin Infect Dis"},{"key":"31_CR36","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1086\/430352","volume":"191","author":"JA Silverman","year":"2005","unstructured":"Silverman JA, Mortin LI, Vanpraagh AD, et al.: Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005, 191:2149\u20132152.","journal-title":"J Infect Dis"},{"key":"31_CR37","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/00006454-200206000-00010","volume":"21","author":"AL Frank","year":"2002","unstructured":"Frank AL, Marcinak JF, Mangat PD, et al.: Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002, 21:530\u2013534.","journal-title":"Pediatr Infect Dis J"},{"key":"31_CR38","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/00006454-200307000-00006","volume":"22","author":"G Martinez-Aguilar","year":"2003","unstructured":"Martinez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL: Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003, 22:593\u2013598. This retrospective study compared the outcome of therapy for invasive infections due to CA-MRSA in 46 children with that of community-acquired methicillin-susceptible S. aureus infections in 53 children treated with clindamycin, vancomycin or \u03b2-lactam antibiotics. The authors note that their study supports the use of clindamycin as empiric treatment in children suspected to be due to CA-MRSA in their community, where the frequence of MLSB resistance was very low.","journal-title":"Pediatr Infect Dis J"},{"key":"31_CR39","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1086\/377501","volume":"37","author":"GK Siberry","year":"2003","unstructured":"Siberry GK, Tekle T, Carroll K, Dick J: Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003, 37:1257\u20131260.","journal-title":"Clin Infect Dis"},{"key":"31_CR40","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1086\/367662","volume":"36","author":"GM Eliopoulos","year":"2003","unstructured":"Eliopoulos GM: Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003, 36:473\u2013481.","journal-title":"Clin Infect Dis"},{"key":"31_CR41","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.43.5.1062","volume":"43","author":"G Lina","year":"1999","unstructured":"Lina G, Quaglia A, Reverdy ME, Leclercq R, et al.: Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999, 43:1062\u20131066.","journal-title":"Antimicrob Agents Chemother"},{"key":"31_CR42","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1128\/AAC.44.10.2880-2882.2000","volume":"44","author":"PC Fuchs","year":"2000","unstructured":"Fuchs PC, Barr AL, Brown SD: Bactericidal activity of quinupristin\/ dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator. Antimicrob Agents Chemother 2000, 44:2880\u20132882.","journal-title":"Antimicrob Agents Chemother"},{"key":"31_CR43","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/AAC.39.2.400","volume":"39","author":"B Fantin","year":"1995","unstructured":"Fantin B, Leclerq R, Merl\u00e9 Y, et al.: Critical influence of resistance to streptogramin B type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due Staphylococcus aureus. Antimicrob Agents Chemother 1995, 39:400\u2013405.","journal-title":"Antimicrob Agents Chemother"},{"key":"31_CR44","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1128\/AAC.44.5.1168-1173.2000","volume":"44","author":"V Zarrouk","year":"2000","unstructured":"Zarrouk V, Bozdogan B, Leclercq R, et al.: Influence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother 2000, 44:1168\u20131173.","journal-title":"Antimicrob Agents Chemother"},{"key":"31_CR45","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1128\/AAC.44.7.1789-1795.2000","volume":"44","author":"J Vouillamoz","year":"2000","unstructured":"Vouillamoz J, Entenza JM, Feger C, et al.: Quinupristindalfopristin combined with \u00df-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolides-lincosamidesstreptogramin B Antibiotics. Antimicrob Agents Chemother 2000, 44:1789\u20131795.","journal-title":"Antimicrob Agents Chemother"},{"key":"31_CR46","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1128\/AAC.46.9.3061-3064.2002","volume":"46","author":"P Pavie","year":"2002","unstructured":"Pavie P, Lefort A, Zarrouk V, et al.: Efficacies of Quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics. Antimicrob Agents Chemother 2002, 46:3061\u20133064.","journal-title":"Antimicrob Agents Chemother"},{"key":"31_CR47","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1128\/AAC.38.3.432","volume":"38","author":"B Fantin","year":"1994","unstructured":"Fantin B, Leclercq R, Ottaviani M, et al.: In vivo activities and penetration of RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother 1994, 38:432\u2013437.","journal-title":"Antimicrob Agents Chemother"},{"key":"31_CR48","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1128\/AAC.45.4.1244-1248.2001","volume":"45","author":"V Zarrouk","year":"2001","unstructured":"Zarrouk V, Bozdogan B, Leclercq R, et al.: Activities of the combination of quinupristin-dalfopristin and rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics. Antimicrob Agents Chemother 2001, 45:1244\u20131248.","journal-title":"Antimicrob Agents Chemother"},{"key":"31_CR49","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/340353","volume":"34","author":"DL Stevens","year":"2002","unstructured":"Stevens DL, Herr D, Lampiris H, et al.: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002, 34:1481\u20131490.","journal-title":"Clin Infect Dis"},{"key":"31_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/109629603764655290","volume":"4","author":"JZ Li","year":"2003","unstructured":"Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ: Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surgical Infect 2003, 4:57\u201370.","journal-title":"Surgical Infect"},{"key":"31_CR51","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00134-003-2135-y","volume":"30","author":"MH Kollef","year":"2004","unstructured":"Kollef MH, Rello J, Cammarata SK, et al.: Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blinded studies comparing linezolid with vancomycin. Intensive Care Med 2004, 30:343\u2013346. This is a retrospective analysis of two randomized, double-blind multinational studies with 134 sites. Outcomes were assessed in 544 patients with suspected gram-positive ventilator-associated pneumonia (VAP), including 264 with documented gram-positive VAP and 91 with MRSA VAP who were treated with either linezolid 600 mg or vancomycin 1 gram every 12 hours for 7 to 21 days, each with aztreonam.","journal-title":"Intensive Care Med"},{"key":"31_CR52","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S1473-3099(04)01109-0","volume":"4","author":"AM Bressler","year":"2004","unstructured":"Bressler AM, Zimmer SM, Gilmore JL, Somani J: Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004, 4:528\u2013531.","journal-title":"Lancet Infect Dis"},{"key":"31_CR53","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1086\/379012","volume":"37","author":"E Lee","year":"2003","unstructured":"Lee E, Burger S, Shah J, et al.: Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003, 37:1389\u20131391.","journal-title":"Clin Infect Dis"},{"key":"31_CR54","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/jac\/dkh199","volume":"53","author":"F Frippiat","year":"2004","unstructured":"Frippiat F, Bergiers C, Michel C, et al.: Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 2004, 53:1114\u20131115.","journal-title":"J Antimicrob Chemother"},{"key":"31_CR55","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1086\/378895","volume":"37","author":"PK Gillman","year":"2003","unstructured":"Gillman PK: Linezolid and serotonin toxicity. Clin Infect Dis 2003, 37:1274\u20131275.","journal-title":"Clin Infect Dis"},{"key":"31_CR56","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1086\/374558","volume":"36","author":"L Bernard","year":"2003","unstructured":"Bernard L, Stern R, Lew D, Hoffmeyer P: Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 2003, 36:1197.","journal-title":"Clin Infect Dis"},{"key":"31_CR57","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1128\/AAC.44.8.2225-2229.2000","volume":"44","author":"HW Boucher","year":"2000","unstructured":"Boucher HW, Wennerstein CB, Eliopoulos GM: In vitro activity of the glycylcycline GAR-936 against grampositive bacteria. Antimicrob Agents Chemother 2000, 44:2225\u20132229.","journal-title":"Antimicrob Agents Chemother"},{"key":"31_CR58","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-117-5-390","volume":"117","author":"N Markowitz","year":"1992","unstructured":"Markowitz N, Quinn EL, Saravolatz LD: Trimethoprim\/ Sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infections. Ann Intern Med 1992, 117:390\u2013398.","journal-title":"Ann Intern Med"},{"key":"31_CR59","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1172\/JCI107348","volume":"52","author":"GL Mandell","year":"1973","unstructured":"Mandell GL: Interaction of intraleukocytic bacteria and antibiotics. J Clin Invest 1973, 52:1673\u20131679.","journal-title":"J Clin Invest"},{"key":"31_CR60","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","volume":"279","author":"W Zimmerli","year":"1998","unstructured":"Zimmerli W, Widmer AF, Blatter M, et al.: Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-body infection (FBI) study group. JAMA 1998, 279:1537\u20131541.","journal-title":"JAMA"},{"key":"31_CR61","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/00007611-198608000-00008","volume":"79","author":"CW Norden","year":"1986","unstructured":"Norden CW, Bryant R, Palmer D, et al.: Chronic osteomyeli tis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986, 79:947\u2013951.","journal-title":"South Med J"},{"key":"31_CR62","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1128\/AAC.44.11.3229-3231.2000","volume":"44","author":"FJ Schmitz","year":"2000","unstructured":"Schmitz FJ, Fluit AC, Hafner D, et al.: Development of resistance to ciprofloxacin, rifampin and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2000, 44:3229\u20133231.","journal-title":"Antimicrob Agents Chemother"},{"key":"31_CR63","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijantimicag.2004.03.009","volume":"24","author":"B Shopsin","year":"2004","unstructured":"Shopsin B, Zhao X, Kreiswirth BN, et al.: Are the new quinolone appropriate treatment for communityacquired methicillin-resistant Staphylococcus aureus? Int J Antimicrob Agents 2004, 24:32\u201334.","journal-title":"Int J Antimicrob Agents"},{"key":"31_CR64","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1128\/AAC.47.5.1604-1613.2003","volume":"47","author":"AA Firsov","year":"2003","unstructured":"Firsov AA, Vostrov SN, Lubenko IY, et al.: In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47:1604\u20131613.","journal-title":"Antimicrob Agents Chemother"},{"key":"31_CR65","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ijantimicag.2003.11.006","volume":"23","author":"AA Firsov","year":"2004","unstructured":"Firsov AA, Vostrov SN, Lubenko IY, et al.: Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. J Antimicrob Agents 2004, 23:451\u2013456.","journal-title":"J Antimicrob Agents"},{"key":"31_CR66","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S0149-2918(04)90070-7","volume":"26","author":"PO Postier","year":"2004","unstructured":"Postier PO, Green SL, Klein SR, et al.: Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Therapeutics 2004, 26:704\u2013714. In this study, in the 81 patients with complicated skin and skinstructure infections who received the 50-mg doses of tigecycline every 12 hours (the recommended dose for tigecycline), the clinical cure rate and microbiologic eradication rate were 74% and 69%, respectively, but only four patients had infection due to MRSA and 20 due to methillicin-susceptible S. aureus.","journal-title":"Clin Therapeutics"},{"key":"31_CR67","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa042683","volume":"352","author":"LG Miller","year":"2005","unstructured":"Miller LG, Perdreau-Remington F, Rieg G, et al.: Necrotizing fasciitis caused by Community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005, 352:1445\u20131453. This paper describes 14 cases of necrotizing fasciitis due to CAMRSA that occurred in Los Angeles between January 2003 and April 2004. All required surgery; 10 required intensive care, but all survived an illness that frequently has a high mortality rate. Ten had underlying conditions that suggested prior contact with the health care system.","journal-title":"N Engl J Med"},{"key":"31_CR68","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1086\/430910","volume":"41","author":"AI Hidron","year":"2005","unstructured":"Hidron AI, Kourbatova EV, Halvosa JS, et al.: Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: Emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005, 41:159\u2013166.","journal-title":"Clin Infect Dis"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-006-0031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11908-006-0031-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-006-0031-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-006-0031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:36:50Z","timestamp":1744166210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11908-006-0031-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["31"],"URL":"https:\/\/doi.org\/10.1007\/s11908-006-0031-7","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"type":"print","value":"1523-3847"},{"type":"electronic","value":"1534-3146"}],"subject":[],"published":{"date-parts":[[2006,2]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}